Evidence map›Paper›PMID 35525557›Full record

ArticleMethods in enzymology2022

An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations.

Raphael Trenker, Devan Diwanji, Kliment A Verba, Natalia Jura

Open access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
7.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Raphael TrenkerCardiovascular Research Institute, University of California San Francisco, San Francisco, CA, United States.
Devan DiwanjiCardiovascular Research Institute, University of California San Francisco, San Francisco, CA, United States; Medical Scientist Training Program, University of California San Francisco, San Francisco, CA, United States.
Kliment A VerbaQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, United States; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, United States. Electronic address: kliment.verba@ucsf.edu.
Natalia JuraCardiovascular Research Institute, University of California San Francisco, San Francisco, CA, United States; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, United States. Electronic address: natalia.jura@ucsf.edu.
University of California, San Francisco · US

Funding

Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY · 2017 to 2021
$10.9M
Structural and Functional Studies of HER ReceptorsR35GM139636 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natalia Jura · 2021 to 2026
$2.5M
Investigating oncogenic mutations and regulatory mechanisms of HER2 by electron microscopyF30CA247147 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DIWANJI, DEVAN · 2020 to 2023
$163k
NCI NIH HHS F30 CA247147NCI NIH HHS U54 CA209891NIGMS NIH HHS R35 GM139636
6 · The paper itself

Abstract

Obtaining high-resolution structures of Receptor Tyrosine Kinases that visualize extracellular, transmembrane and intracellular kinase regions simultaneously is an eagerly pursued but still unmet challenge of structural biology. The Human Epidermal Growth Factor Receptor 3 (HER3) that has a catalytically inactive kinase domain (pseudokinase) forms a potent signaling complex upon binding of growth factor neuregulin 1β (NRG1β) and upon dimerization with a close homolog, the HER2 receptor. The HER2/HER3/NRG1β complex is often referred to as an oncogenic driver in breast cancer and is an attractive target for anti-cancer therapies. After overcoming significant hurdles in isolating sufficient amounts of the HER2/HER3/NRG1β complex for structural studies by cryo-electron microscopy (cryo-EM), we recently obtained the first high-resolution structures of the extracellular portion of this complex. Here we describe a step-by-step protocol for obtaining a stable and homogenous HER2/HER3/NRG1β complex for structural studies and our recommendation for collecting and processing cryo-EM data for this sample. We also show improved EM density for the transmembrane and kinase domains of the receptors, which continue to evade structural determination at high resolution. The discussed strategies are tunable and applicable to other membrane receptor complexes.

Indexed as

Breast NeoplasmsReceptor, ErbB-3Cryoelectron MicroscopyErb-b2 Receptor Tyrosine KinasesFemaleHumansLigandsErb-b2 Receptor Tyrosine KinasesLigandsReceptor, ErbB-3Cryo-electron microscopyGrowth factorKinase activationLigand bindingProtein purificationReceptor tyrosine kinasesSignalingStructural biology

Identifiers

PMID35525557
PMCPMC9288110
OpenAlexW4226167102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.